Favicon
Favicon

Alter awarded NIH grant for innovative HIV vaccine approach

Date: August 21, 2012 By:

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine. The grants were awarded under the Innovation for HIV Vaccine Discovery (IHVD) initiative, which is expected to receive up to $34.8 million over the next four years.

 

“Recent discoveries about the basic biology of HIV and how the virus adapts to its host have provided useful information and new opportunities to guide vaccine development,” said NIAID Director Anthony S. Fauci, M.D. “These grants are designed to build on that information and stimulate discovery of new ways to design a robust vaccine that prevents acquisition and establishment of latent infection.”

 

Ragon Institute Investigator Dr. Galit Alter was one of 14 recipients of this NIAID grant.

 

View full list of awardees  (via NIAID)

More News

Ragon Institute Introduces Catherine Othieno Sempa Memorial Post Baccalaureate Scholars Program

The Catherine Othieno Sempa* Memorial Post Baccalaureate Scholars Program engages talented college graduates from HBCUs and Puerto Rican universities in a comprehensive and immersive two-year program in immunology research.

Awards

Hernandez Moura Silva Awarded MLK Leadership Award from MIT

Ragon faculty member Hernandez Moura Silva, PhD, was recently awarded the MIT 2024 Martin Luther King Jr. Leadership Award for faculty.

Press Releases

PRESS RELEASE – Ragon faculty study finds combination of two drugs increases the vulnerability of HIV-1 reservoir cells to the immune system.

Ragon faculty Mathias Lichterfeld, MD, PhD, and Xu Yu, MD, have co-authored a paper published in Cell which found evidence that a combination of two drugs increases the vulnerability of HIV-1 reservoir cells to the immune system — which shows promising results in targeting and reducing the HIV-1 reservoir in people living with HIV.